Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

800 trials with published results (22%)

Research Maturity

2628 completed trials (72% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.5%

199 terminated out of 3626 trials

Success Rate

93.0%

+6.5% vs benchmark

Late-Stage Pipeline

23%

835 trials in Phase 3/4

Results Transparency

30%

800 of 2628 completed with results

Key Signals

800 with results93% success199 terminated

Data Visualizations

Phase Distribution

2,663Total
Not Applicable (948)
Early P 1 (24)
P 1 (338)
P 2 (518)
P 3 (476)
P 4 (359)

Trial Status

Completed2,628
Unknown333
Terminated199
Recruiting199
Withdrawn116
Active Not Recruiting72

Trial Success Rate

93.0%

Benchmark: 86.5%

Based on 2628 completed trials

Clinical Trials (3626)

Showing 20 of 20 trials
NCT06676319Phase 2RecruitingPrimary

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT01678222Completed

The COX-2 Gene and the Immune System

NCT05097287Phase 4Active Not RecruitingPrimary

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

NCT07533565Phase 4Completed

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

NCT07394127Not ApplicableCompleted

Effects of Inspiratory Muscle Training Added to a Swimming Program in Children With Asthma

NCT00001532Recruiting

Role of Genetic Factors in the Development of Lung Disease

NCT01399411CompletedPrimary

Agricultural Health Study Follow-up

NCT02127866Phase 2CompletedPrimary

Triple in Asthma Dose Finding

NCT06506266Phase 1CompletedPrimary

Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants

NCT01143480RecruitingPrimary

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

NCT06264674Phase 3CompletedPrimary

Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

NCT06471257Phase 3RecruitingPrimary

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

NCT01780142CompletedPrimary

Longitudinal Observational Study of Severe Asthma

NCT02636933TerminatedPrimary

Longitudinal Observational Study in Prematurely Born Preschool Children: Assessment of Lung Function Parameters

NCT07523724Not ApplicableNot Yet RecruitingPrimary

Screening and Management of Adults With Asthma and Allergic Diseases

NCT07241546Phase 2RecruitingPrimary

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

NCT07525375Phase 2Not Yet RecruitingPrimary

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

NCT06657807Not ApplicableRecruitingPrimary

Online Cognitive Behavior Therapy for Anxiety Related to Pediatric Asthma

NCT07524543RecruitingPrimary

International Severe Asthma Registry_Hong Kong

NCT02433275CompletedPrimary

CHildhood ASthma and Environment Research Study - CHASER Study

Scroll to load more

Research Network

Activity Timeline